Soluble VCAM-1 predicts outcome
The second article, by Mulvihill and colleagues, 7 highlights the use of soluble adhesion molecules as markers of inflammatory activity in ACS. E-and P-selectin, ICAM-1, and VCAM-1 are all adhesion molecules that show increased expression by endothelial cells in response to cytokines and other stimuli, and which are involved in guiding circulating leucocytes into inflamed tissues. 8 9 Initial tethering and rolling of neutrophils on vascular endothelium is mediated by transient interactions between selectins (L-selectin on leucocytes, E-selectin on activated endothelial cells, and P-selectin on both activated endothelial cells and activated platelets) and their glycosylated receptors on the opposing cell. While rolling, neutrophils become activated by local chemoattractants, resulting in the stimulation of firm adhesion through 2 integrin (CD11a/CD18, CD11b/CD18) interactions with ICAM-1 and ICAM-2. Monocytes may also employ these molecules and, additionally, may tether, roll, and firmly adhere through interactions between the 4 integrin VLA-4 (CD49d/CD29) and VCAM-1. Since P-selectin, E-selectin, ICAM-1, and VCAM-1 are each shed from cell surfaces into extracellular fluid, concentrations of the circulating extracellular domains of soluble molecules have been considered to be a reflection of their surface expression in the tissues, and hence have been used as markers of inflammatory activity. 10 11 It is debatable whether circulating adhesion molecules are functionally important, or are merely awaiting clearance and degradation.
The study of Mulvihill and colleagues 7 sets out to determine whether measurement of concentrations of the four soluble adhesion molecules during acute presentation with unstable angina or non-Q wave myocardial infarction predicted outcome over six months of follow up, and to compare prognostic accuracy with C-reactive protein (CRP). 12 In a previous study, this group found that concentrations of all four soluble adhesion molecules were increased in patients with unstable angina or non-Q wave myocardial infarction. Now, they show that concentrations of soluble VCAM-1 correlated strongly with the occurrence of a major adverse cardiovascular event within six months, whereas concentrations of soluble P-selectin, E-selectin, and ICAM-1 do not. Although it would be a mistake to overinterpret these observations in terms of pathophysiology, it is interesting that ICAM-1 but not VCAM-1 has been found in prospective epidemiological studies to be a risk factor for future coronary events. 11 13 It is possible therefore that increased soluble VCAM-1 and ICAM-1 expression reflect the diVerent facets of acute and chronic coronary artery disease. It is also possible that increased soluble VCAM-1 might reflect cardiomyocyte injury, since no information on troponin concentrations in these patients is provided.
If the degree of inflammation predicts outcome, what inflammatory markers might the clinician measure in patients upon presentation with unstable angina? Mulvihill and colleagues found that a CRP concentration of < 3 mg/l had a negative predictive value for major adverse cardiovascular events within six months of 97%. 7 Conversely a CRP concentration of > 3 mg/l had a sensitivity of 96% for predicting adverse cardiovascular events, albeit with a specificity of 52%. CRP was as sensitive as soluble VCAM-1 for predicting major adverse events, and measuring VCAM-1 did not appear to add to CRP's predictive accuracy. Whether measuring cytokines such as IL-6 or surface expression of leucocyte activation antigens (for example, CD11b/CD18) provides further information remains to be determined, but arguably measurement of CRP, which is readily available and relatively cheap, may be suYcient for evaluating ongoing inflammation as a risk for poor outcome, particularly if measured at discharge rather than admission. 14 
Therapeutic implications
What potential does the recent burst of information on inflammation and coronary artery disease have for influencing treatment? Although eYcacy in animal models prompted the trial of anti-2 integrin antibodies in acute coronary syndromes, results from clinical trials have so far been disappointing. 15 While we continue to consider other options, we should not forget that drugs used currently may act partly through anti-inflammatory mechanisms. Although aspirin obviously has anti-inflammatory properties, at the low doses used in cardiological practice the main action is probably on platelets. On the other hand, inhibitors of the renin-angiotensin system may block the activation by angiotensin II of NADP(H) oxidase and subsequent superoxide production, 16 and also inhibit the activation by angiotensin II of endothelial cell NF B activation and VCAM-1 expression. 17 Lastly, there is an emerging literature that HMG-CoA reductase inhibitors have anti-inflammatory and immunomodulatory actions that are not simply due to lowering cholesterol, 18 and it is possible that such properties might beneficially influence adverse events if a statin is introduced acutely in unstable angina. 
